Top

Current Osteoporosis Reports

Published in:

01-02-2017 | Kidney and Bone (S Moe and I Salusky, Section Editors)

The Role of TGFβ in Bone-Muscle Crosstalk

Authors: Jenna N. Regan, Trupti Trivedi, Theresa A. Guise, David L. Waning

Published in: Current Osteoporosis Reports | Issue 1/2017

Abstract

Purpose of Review

The role of bone-derived factors in regulation of skeletal muscle function is an important emerging aspect of research into bone-muscle crosstalk. Implications for this area of research are far reaching and include understanding skeletal muscle weakness in cancer, osteoporosis, cachexia, rare diseases of bone, and aging.

Recent Findings

Recent research shows that bone-derived factors can lead to changes in the skeletal muscle. These changes can either be anabolic or catabolic, and we focus this review on the role of TGFβ in driving oxidative stress and skeletal muscle weakness in the setting of osteolytic cancer in the bone.

Summary

The bone is a preferred site for breast cancer metastasis and leads to pathological bone loss. Osteolytic cancer in the bone leads to release of TGFβ from the bone via osteoclast-mediated bone destruction. Our appreciation of crosstalk between the muscle and bone has recently expanded beyond mechanical force-driven events to encompass a variety of signaling factors originating in one tissue and communicating to the other. This review summarizes some previously known mediators of bone-to-muscle signaling and also recent work identifying a new role for bone-derived TGFβ as a cause of skeletal muscle weakness in the setting of osteolytic cancer in the bone. Multiple points of potential therapeutic intervention are discussed.

Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-sepharose. J Biol Chem. 1986;261(27):12665–74.PubMed

Oldknow KJ, MacRae VE, Farquharson C. Endocrine role of bone: recent and emerging perspectives beyond osteocalcin. J Endocrinol. 2015;225(1):R1–19. doi:10.1530/JOE-14-0584.CrossRefPubMed

Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Rev Endocr Metab Disord. 2015;16(2):93–8. doi:10.1007/s11154-014-9307-7.CrossRefPubMedPubMedCentral

Regan JN, Waning DL, Guise TA. Skeletal muscle Ca(2+) mishandling: another effect of bone-to-muscle signaling. Semin Cell Dev Biol. 2016;49:24–9. doi:10.1016/j.semcdb.2015.11.007.CrossRefPubMed

• Levinger I, Scott D, Nicholson GC, Stuart AL, Duque G, McCorquodale T, et al. Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 2014;64:8–12. doi:10.1016/j.bone.2014.03.008. This study shows an age-adjusted association between lower limb strength and osteocalcin in humansCrossRefPubMed

Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142(2):296–308. doi:10.1016/j.cell.2010.06.003.CrossRefPubMedPubMedCentral

Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142(2):309–19. doi:10.1016/j.cell.2010.06.002.CrossRefPubMedPubMedCentral

Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130(3):456–69. doi:10.1016/j.cell.2007.05.047.CrossRefPubMedPubMedCentral

Shen H, Grimston S, Civitelli R, Thomopoulos S. Deletion of connexin43 in osteoblasts/osteocytes leads to impaired muscle formation in mice. J Bone Miner Res. 2015;30(4):596–605. doi:10.1002/jbmr.2389.CrossRefPubMedPubMedCentral

10.

Wildemann B, Kadow-Romacker A, Haas NP, Schmidmaier G. Quantification of various growth factors in different demineralized bone matrix preparations. J Biomed Mater Res A. 2007;81(2):437–42. doi:10.1002/jbm.a.31085.CrossRefPubMed

11.

Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle. 2011;1(1):4. doi:10.1186/2044-5040-1-4.CrossRefPubMedPubMedCentral

12.

Blaauw B, Canato M, Agatea L, Toniolo L, Mammucari C, Masiero E, et al. Inducible activation of Akt increases skeletal muscle mass and force without satellite cell activation. FASEB J. 2009;23(11):3896–905. doi:10.1096/fj.09-131870.CrossRefPubMed

13.

•• Sartori R, Schirwis E, Blaauw B, Bortolanza S, Zhao J, Enzo E, et al. BMP signaling controls muscle mass. Nat Genet. 2013;45(11):1309–18. doi:10.1038/ng.2772. This paper describes the role of BMPs in maintenance of the muscle. Signaling through SMAD1/5/8 causes muscle hypertrophy and counteracts muscle atrophy signals through regulation of ubiquitin-mediated protein degradationCrossRefPubMed

14.

Winbanks CE, Chen JL, Qian H, Liu Y, Bernardo BC, Beyer C, et al. The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. J Cell Biol. 2013;203(2):345–57. doi:10.1083/jcb.201211134.CrossRefPubMedPubMedCentral

15.

Sartori R, Gregorevic P, Sandri M. TGFbeta and BMP signaling in skeletal muscle: potential significance for muscle-related disease. Trends Endocrinol Metab. 2014;25(9):464–71. doi:10.1016/j.tem.2014.06.002.CrossRefPubMed

16.

Kamel MA, Picconi JL, Lara-Castillo N, Johnson ML. Activation of beta-catenin signaling in MLO-Y4 osteocytic cells versus 2 T3 osteoblastic cells by fluid flow shear stress and PGE2: implications for the study of mechanosensation in bone. Bone. 2010;47(5):872–81. doi:10.1016/j.bone.2010.08.007.CrossRefPubMedPubMedCentral

17.

Ajubi NE, Klein-Nulend J, Nijweide PJ, Vrijheid-Lammers T, Alblas MJ, Burger EH. Pulsating fluid flow increases prostaglandin production by cultured chicken osteocytes—a cytoskeleton-dependent process. Biochem Biophys Res Commun. 1996;225(1):62–8. doi:10.1006/bbrc.1996.1131.CrossRefPubMed

18.

Kitase Y, Barragan L, Qing H, Kondoh S, Jiang JX, Johnson ML, et al. Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the beta-catenin and PKA pathways. J Bone Miner Res. 2010;25(12):2657–68. doi:10.1002/jbmr.168.CrossRefPubMedPubMedCentral

19.

Harada SI, Balena R, Rodan GA, Rodan SB. The role of prostaglandins in bone formation. Connect Tissue Res. 1995;31(4):279–82.CrossRefPubMed

20.

Mo C, Romero-Suarez S, Bonewald L, Johnson M, Brotto M. Prostaglandin E2: from clinical applications to its potential role in bone-muscle crosstalk and myogenic differentiation. Recent Pat Biotechnol. 2012;6(3):223–9.CrossRefPubMedPubMedCentral

21.

Aono Y, Hasegawa H, Yamazaki Y, Shimada T, Fujita T, Yamashita T, et al. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res. 2011;26(4):803–10. doi:10.1002/jbmr.275.CrossRefPubMed

22.

Waning DL, Guise TA. Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 2014;20(12):3071–7. doi:10.1158/1078-0432.CCR-13-1590.CrossRefPubMedPubMedCentral

23.

Wacker MJ, Touchberry CD, Silswal N, Brotto L, Elmore CJ, Bonewald LF, et al. Skeletal muscle, but not cardiovascular function, is altered in a mouse model of autosomal recessive hypophosphatemic rickets. Front Physiol. 2016;7:173. doi:10.3389/fphys.2016.00173.CrossRefPubMedPubMedCentral

24.

Bonewald LF, Mundy GR. Role of transforming growth factor-beta in bone remodeling. Clin Orthop Relat Res. 1990;250:261–76.

25.

• Dallas SL, Rosser JL, Mundy GR, Bonewald LF, et al. J Biol Chem. 2002;277(24):21352–60. doi:10.1074/jbc.M111663200. The release of TGFb from mineralized bone matrix is critical for normal bone remodeling and plays a large role in pathophysiological effects in the bone. This paper provides the mechanism for release of TGFb from boneCrossRefPubMed

26.

Sakai R, Eto Y. Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol. 2001;180(1–2):183–8.CrossRefPubMed

27.

Chen JL, Walton KL, Winbanks CE, Murphy KT, Thomson RE, Makanji Y, et al. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014;28(4):1711–23. doi:10.1096/fj.13-245894.CrossRefPubMed

28.

•• Mendias CL, Gumucio JP, Davis ME, Bromley CW, Davis CS, Brooks SV. Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 2012;45(1):55–9. doi:10.1002/mus.22232. This paper describes the role of TGFb in skeletal muscle weakness. This was the first report of muscle functional status modulation directly by TGFbCrossRefPubMedPubMedCentral

29.

Lam K, Chow E, Zhang L, Wong E, Bedard G, Fairchild A, et al. Determinants of quality of life in advanced cancer patients with bone metastases undergoing palliative radiation treatment. Support Care Cancer. 2013;21(11):3021–30. doi:10.1007/s00520-013-1876-6.CrossRefPubMed

30.

Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110(8):1860–7. doi:10.1002/cncr.22991.CrossRefPubMed

31.

Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275–92. doi:10.1016/j.cell.2011.09.024.CrossRefPubMedPubMedCentral

32.

Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 2011;20(6):701–14. doi:10.1016/j.ccr.2011.11.002.CrossRefPubMedPubMedCentral

33.

Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153(3):865–73. doi:10.1016/S0002-9440(10)65628-3.CrossRefPubMedPubMedCentral

34.

Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res. 2007;13(17):5001–9. doi:10.1158/1078-0432.CCR-07-0024.CrossRefPubMedPubMedCentral

35.

Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11(6):411–25. doi:10.1038/nrc3055.CrossRefPubMedPubMedCentral

36.

Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. 2010;285(33):25103–8. doi:10.1074/jbc.R109.041087.CrossRefPubMedPubMedCentral

37.

Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone. 2011;49(1):56–65. doi:10.1016/j.bone.2010.10.159.CrossRefPubMed

38.

Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A. 2005;102(39):13909–14. doi:10.1073/pnas.0506517102.CrossRefPubMedPubMedCentral

39.

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537–49.CrossRefPubMed

40.

• Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15(8):960–6. doi:10.1038/nm.1943. This paper describes the utility of TGFb inhibition in early bone metastases and shows that the largest source of TGFb in mice with osteolytic breast cancer bone metastases is from the mineralized bone matrixCrossRefPubMed

41.

Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103(2):197–206. doi:10.1172/JCI3523.CrossRefPubMedPubMedCentral

42.

•• Waning DL, Mohammad KS, Reiken S, Xie W, Andersson DC, John S, et al. Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat Med. 2015;21(11):1262–71. doi:10.1038/nm.3961. This paper describes the novel TGFb-Nox4-RyR1 axis that is altered in osteolytic cancer in the bone. The mechanism of muscle weakness in these studies is via increased oxidative stress and sarcoplamic reticulum calcium leakCrossRefPubMedPubMedCentral

43.

Andersson DC, Betzenhauser MJ, Reiken S, Meli AC, Umanskaya A, Xie W, et al. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 2011;14(2):196–207. doi:10.1016/j.cmet.2011.05.014.CrossRefPubMedPubMedCentral

44.

Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, et al. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat Med. 2009;15(3):325–30. doi:10.1038/nm.1916.CrossRefPubMedPubMedCentral

45.

Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 2009;4(9):e6896. doi:10.1371/journal.pone.0006896.CrossRefPubMedPubMedCentral

46.

Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 2004;109(2):227–33. doi:10.1161/01.CIR.0000105680.92873.70.CrossRefPubMed

47.

Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem. 2010;53(21):7715–30. doi:10.1021/jm100773e.CrossRefPubMed

48.

Lee EM, Kim DY, Kim AY, Lee EJ, Kim SH, Lee MM, et al. Chronic effects of losartan on the muscles and the serologic profiles of mdx mice. Life Sci. 2015;143:35–42. doi:10.1016/j.lfs.2015.10.023.CrossRefPubMed

49.

Taniguti AP, Pertille A, Matsumura CY, Santo Neto H, Marques MJ. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blocker. Muscle Nerve. 2011;43(1):82–7. doi:10.1002/mus.21869.CrossRefPubMed

Title: The Role of TGFβ in Bone-Muscle Crosstalk
Authors: Jenna N. Regan
Trupti Trivedi
Theresa A. Guise
David L. Waning
Publication date: 01-02-2017
Publisher: Springer US
Published in: Current Osteoporosis Reports / Issue 1/2017
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-017-0344-5

At a glance: The STEP trials

Springer Medicine

The Role of TGFβ in Bone-Muscle Crosstalk

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2017

Physical Activity for Strengthening Fracture Prone Regions of the Proximal Femur

Connexin43 and the Intercellular Signaling Network Regulating Skeletal Remodeling

Clinical Evaluation of Bone Strength and Fracture Risk

Genetic Disorders of Dental Development: Tales from the Bony Crypt

Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone?